Rnai screening identifies tak1 as a potential target for the enhanced efficacy of topoisomerase inhibitors

Current Cancer Drug Targets

Volumn 11, Issue 8, 2011, Pages 976-986

  Martin, S E ^a,c   Wu, Z H ^b   Gehlhaus, K ^a   Jones, T L ^a   Zhang, Y W ^c   Guha, R ^c   Miyamoto, S ^b   Pommier, Y ^c   Caplen, N J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Camptothecin; Map3k7; Rnai; Screen; Sirna; Tab2; Tak1; Traf6

Indexed keywords

ALPHA TUBULIN; CAMPTOTHECIN; CASPASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE P38; OCTAMER TRANSCRIPTION FACTOR 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TOPOTECAN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; GENE; GENE SILENCING; HUMAN; HUMAN CELL; MAP3K7 GENE; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAB2 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOPOISOMERASE INHIBITORS;

EID: 80052825075     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911797264734     Document Type: Article

References (59)

1. Collins, I.; Workman, P. New approaches to molecular cancer therapeutics. Nat. Chem. Biol. 2006, 2, 689-700.
2. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1, 493-502.
3. Johnston, J. B.; Navaratnam, S.; Pitz, M. W.; Maniate, J. M.; Wiechec, E.; Baust, H.; Gingerich, J.; Skliris, G. P.; Murphy, L. C.; Los, M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 2006, 13, 3483-3492.
4. Martin, S. E.; Caplen, N. J. Applications of RNA interference in mammalian systems. Annu. Rev. Genomics Hum. Genet. 2007, 8, 81-108.
5. Iorns, E.; Turner, N. C.; Elliott, R.; Syed, N.; Garrone, O.; Gasco, M.; Tutt, A. N.; Crook, T.; Lord, C. J.; Ashworth, A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 2008, 13, 91-104.
6. Lord, C. J.; McDonald, S.; Swift, S.; Turner, N. C.; Ashworth, A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7, 2010-2019.
7. Turner, N. C.; Lord, C. J.; Iorns, E.; Brough, R.; Swift, S.; Elliott, R.; Rayter, S.; Tutt, A. N.; Ashworth, A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008, 27, 1368-1377.
8. Chung, N.; Locco, L.; Huff, K. W.; Bartz, S.; Linsley, P. S.; Ferrer, M.; Strulovici, B. An efficient and fully automated high-throughput transfection method for genome-scale siRNA screens. J. Biomol. Screen. 2008, 13, 142-148.
9. MacKeigan, J. P.; Murphy, L. O.; Blenis, J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biology 2005, 7, 591-600.
10. Bartz, S. R.; Zhang, Z.; Burchard, J.; Imakura, M.; Martin, M.; Palmieri, A.; Needham, R.; Guo, J.; Gordon, M.; Chung, N.; Warrener, P.; Jackson, A. L.; Carleton, M.; Oatley, M.; Locco, L.; Santini, F.; Smith, T.; Kunapuli, P.; Ferrer, M.; Strulovici, B.; Friend, S. H.; Linsley, P. S. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 2006, 26, 9377-9386.
11. Giroux, V.; Iovanna, J.; Dagorn, J. C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 2006, 20, 1982-1991.
12. Swanton, C.; Marani, M.; Pardo, O.; Warne, P. H.; Kelly, G.; Sahai, E.; Elustondo, F.; Chang, J.; Temple, J.; Ahmed, A. A.; Brenton, J. D.; Downward, J.; Nicke, B. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007, 11, 498-512.
13. Whitehurst, A. W.; Bodemann, B. O.; Cardenas, J.; Ferguson, D.; Girard, L.; Peyton, M.; Minna, J. D.; Michnoff, C.; Hao, W.; Roth, M. G.; Xie, X. J.; White, M. A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007, 446, 815-819.
14. Azorsa, D. O.; Gonzales, I. M.; Basu, G. D.; Choudhary, A.; Arora, S.; Bisanz, K. M.; Kiefer, J. A.; Henderson, M. C.; Trent, J. M.; Von Hoff, D. D.; Mousses, S. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 2009, 7, 43.
15. Zhang, Y. W.; Jones, T. L.; Martin, S. E.; Caplen, N. J.; Pommier, Y. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J. Biol. Chem. 2009, 284, 18085-18095.
16. Ahmed, A. A.; Wang, X.; Lu, Z.; Goldsmith, J.; Le, X. F.; Grandjean, G.; Bartholomeusz, G.; Broom, B.; Bast, R. C., Jr. Modulating microtubule stability enhances the cytotoxic response of cancer cells to paclitaxel. Cancer Res. 2011.
17. Arora, S.; Bisanz, K. M.; Peralta, L. A.; Basu, G. D.; Choudhary, A.; Tibes, R.; Azorsa, D. O. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol. Oncol. 2010, 118, 220-227.
18. Chen, S.; Blank, J. L.; Peters, T.; Liu, X. J.; Rappoli, D. M.; Pickard, M. D.; Menon, S.; Yu, J.; Driscoll, D. L.; Lingaraj, T.; Burkhardt, A. L.; Chen, W.; Garcia, K.; Sappal, D. S.; Gray, J.; Hales, P.; Leroy, P. J.; Ringeling, J.; Rabino, C.; Spelman, J. J.; Morgenstern, J. P.; Lightcap, E. S. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res. 2010, 70, 4318-4326.
19. Diep, C. H.; Munoz, R. M.; Choudhary, A.; Von Hoff, D. D.; Han, H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin. Cancer Res. 2011, 17, 2744-2756.
20. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
21. Bailly, C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol. 2003, 45, 91-108.
22. Teicher, B. A. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75, 1262-1271.
23. Soule, H. D.; Maloney, T. M.; Wolman, S. R.; Peterson, W. D., Jr.; Brenz, R.; McGrath, C. M.; Russo, J.; Pauley, R. J.; Jones, R. F.; Brooks, S. C. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990, 50, 6075-6086.
24. Huang, T. T.; Wuerzberger-Davis, S. M.; Seufzer, B. J.; Shumway, S. D.; Kurama, T.; Boothman, D. A.; Miyamoto, S. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem. 2000, 275, 9501-9509.
25. Nieves-Neira, W.; Pommier, Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer 1999, 82, 396-404.
26. Brangi, M.; Litman, T.; Ciotti, M.; Nishiyama, K.; Kohlhagen, G.; Takimoto, C.; Robey, R.; Pommier, Y.; Fojo, T.; Bates, S. E. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999, 59, 5938-5946.
27. Doyle, L. A.; Ross, D. D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22, 7340-7358.
28. Cleator, S.; Heller, W.; Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8, 235-244.
29. O'Connor, T.; Rustum, Y.; Levine, E.; Creaven, P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother. Pharmacol. 2008, 61, 125-131.
30. Ninomiya-Tsuji, J.; Kajino, T.; Ono, K.; Ohtomo, T.; Matsumoto, M.; Shiina, M.; Mihara, M.; Tsuchiya, M.; Matsumoto, K. Aresorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 2003, 278, 18485-18490.
31. Adhikari, A.; Xu, M.; Chen, Z. J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007, 26, 3214-3226.
32. Carson, J. P.; Zhang, N.; Frampton, G. M.; Gerry, N. P.; Lenburg, M. E.; Christman, M. F. Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Res. 2004, 64, 2096-2104.
33. Minderman, H.; Conroy, J. M.; O'Loughlin, K. L.; McQuaid, D.; Quinn, P.; Li, S.; Pendyala, L.; Nowak, N. J.; Baer, M. R. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol. Cancer Ther. 2005, 4, 885-900.
34. Morandi, E.; Severini, C.; Quercioli, D.; D'Ario, G.; Perdichizzi, S.; Capri, M.; Farruggia, G.; Mascolo, M. G.; Horn, W.; Vaccari, M.; Serra, R.; Colacci, A.; Silingardi, P. Gene expression timeseries analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines. Mol. Cancer 2008, 7, 66.
35. Morandi, E.; Zingaretti, C.; Chiozzotto, D.; Severini, C.; Semeria, A.; Horn, W.; Vaccari, M.; Serra, R.; Silingardi, P.; Colacci, A. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett. 2006, 231, 74-86.
36. Zhou, Y.; Gwadry, F. G.; Reinhold, W. C.; Miller, L. D.; Smith, L. H.; Scherf, U.; Liu, E. T.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Transcriptional regulation of mitotic genes by camptothecininduced DNA damage: microarray analysis of dose- and timedependent effects. Cancer Res. 2002, 62, 1688-1695.
37. Dutta, J.; Fan, Y.; Gupta, N.; Fan, G.; Gelinas, C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25, 6800-6816.
38. Cuenda, A.; Rousseau, S. P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim. Biophys. Acta 2007, 1773, 1358-1375.
39. Salh, B. C-Jun N-terminal kinases as potential therapeutic targets. Expert Opin. Ther. Targets 2007, 11, 1339-1350.
40. Choo, M. K.; Kawasaki, N.; Singhirunnusorn, P.; Koizumi, K.; Sato, S.; Akira, S.; Saiki, I.; Sakurai, H. Blockade of transforming growth factor-beta-activated kinase 1 activity enhances TRAILinduced apoptosis through activation of a caspase cascade. Mol. Cancer Ther. 2006, 5, 2970-2976.
41. Thiefes, A.; Wolter, S.; Mushinski, J. F.; Hoffmann, E.; Dittrich-Breiholz, O.; Graue, N.; Dorrie, A.; Schneider, H.; Wirth, D.; Luckow, B.; Resch, K.; Kracht, M. Simultaneous blockade of NFkappaB, JNK, and p38 MAPK by a kinase-inactive mutant of the protein kinase TAK1 sensitizes cells to apoptosis and affects a distinct spectrum of tumor necrosis factor [corrected] target genes. J. Biol. Chem. 2005, 280, 27728-27741.
42. Wu, Z. H.; Shi, Y.; Tibbetts, R. S.; Miyamoto, S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006, 311, 1141-1146.
43. Holm, C.; Covey, J. M.; Kerrigan, D.; Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 1989, 49, 6365-6368.
44. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989, 49, 5077-5082.
45. Bonner, W. M.; Redon, C. E.; Dickey, J. S.; Nakamura, A. J.; Sedelnikova, O. A.; Solier, S.; Pommier, Y. GammaH2AX and cancer. Nat. Rev. Cancer 2008, 8, 957-967.
46. Furuta, T.; Takemura, H.; Liao, Z. Y.; Aune, G. J.; Redon, C.; Sedelnikova, O. A.; Pilch, D. R.; Rogakou, E. P.; Celeste, A.; Chen, H. T.; Nussenzweig, A.; Aladjem, M. I.; Bonner, W. M.; Pommier, Y. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 2003, 278, 20303-20312.
47. Rogakou, E. P.; Nieves-Neira, W.; Boon, C.; Pommier, Y.; Bonner, W. M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 2000, 275, 9390-9395.
48. Solier, S.; Sordet, O.; Kohn, K. W.; Pommier, Y. Death receptorinduced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol. Cell. Biol. 2009, 29, 68-82.
49. Morioka, S.; Omori, E.; Kajino, T.; Kajino-Sakamoto, R.; Matsumoto, K.; Ninomiya-Tsuji, J. TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP. Oncogene 2009, 28, 2257-2265.
50. Kim, S.; Kim, Y.; Lee, J.; Chung, J. Regulation of FOXO1 by TAK1-Nemo-like kinase pathway. J. Biol. Chem. 2010, 285, 8122-8129.
51. Nishimura, M.; Shin, M. S.; Singhirunnusorn, P.; Suzuki, S.; Kawanishi, M.; Koizumi, K.; Saiki, I.; Sakurai, H. TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF- {kappa}B-independent survival pathways in tumor necrosis factor alpha signaling. Mol. Cell. Biol. 2009, 29, 5529-5539.
52. Landstrom, M. The TAK1-TRAF6 signalling pathway. Int. J. Biochem. Cell Biol. 2010, 42, 585-589.
53. Hinz, M.; Stilmann, M.; Arslan, S. C.; Khanna, K. K.; Dittmar, G.; Scheidereit, C. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol. Cell 2010, 40, 63-74.
54. Wu, Z. H.; Wong, E. T.; Shi, Y.; Niu, J.; Chen, Z.; Miyamoto, S.; Tergaonkar, V. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 2010, 40, 75-86.
55. Yang, Y.; Xia, F.; Hermance, N.; Mabb, A.; Simonson, S.; Morrissey, S.; Gandhi, P.; Munson, M.; Miyamoto, S.; Kelliher, M. A. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 To mediate the NF-{kappa}B and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol. Cell Biol. 2011, 31, 2774-86.
56. Hadian, K.; Krappmann, D. Signals from the nucleus: activation of NF-kappaB by cytosolic ATM in the DNA damage response. Sci. Signal. 2011, 4, pe2.
57. Safina, A.; Ren, M. Q.; Vandette, E.; Bakin, A. V. TAK1 is required for TGF-beta 1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene 2008, 27, 1198-1207.
58. Safina, A.; Sotomayor, P.; Limoge, M.; Morrison, C.; Bakin, A. V. TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol. Cancer Res. 2011.
59. Neil, J. R.; Schiemann, W. P. Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res. 2008, 68, 1462-1470.